Medical history offers sobering lessons about consensus opinions that later proved incorrect. Physicians once prescribed cigarettes for stress relief. The medical establishment dismissed the link between H. pylori bacteria and stomach ulcers for years. Hormone replacement therapy was widely recommended before studies revealed increased cancer risks. These examples remind us that scientific understanding evolves, sometimes overturning strongly held beliefs.
Today, medical authorities maintain that COVID-19 vaccines do not increase cancer risk. However, emerging research and clinical observations are raising questions that deserve serious scientific scrutiny rather than dismissal. Three recent studies present biological mechanisms and clinical evidence that challenge us to examine this consensus more carefully.
The Clinical Pattern of “Turbo Cancers”
According to research by Marik and Hope in the Journal of Independent Medicine, oncologists worldwide have observed an abrupt increase in cancer incidence beginning in 2021 and continuing through 2023, following widespread COVID-19 vaccination deployment. These cancers, termed “turbo cancers” by clinicians, display distinctive characteristics that set them apart from typical cancer presentations. They appear particularly aggressive, present at late stages, occur in younger patients than expected, and frequently involve uncontrolled relapses in patients previously in remission.
Data from the Vaccine Adverse Event Reporting System (VAERS) reveals that the highest reported cancer risks following vaccination involve the appendix, followed by breast, colorectal, laryngeal, endometrial, and hepatic cancers. Epidemiological data from the United States, United Kingdom, and Japan corroborate these observations, showing excess cancer deaths particularly among individuals aged 75 and older. While correlation does not establish causation, the temporal association between vaccination campaigns and these cancer patterns warrants investigation.
Converging Biological Mechanisms
Research from multiple independent groups has identified overlapping biological pathways through which COVID-19 vaccines might influence cancer development. These mechanisms operate at multiple levels of cellular regulation, from metabolism to immune surveillance.
Metabolic Reprogramming and the Warburg Effect
Marik and Hope describe how the SARS-CoV-2 spike protein induces fundamental metabolic changes in cells, shifting them toward glycolysis even in oxygen-rich conditions. This metabolic reprogramming, known as the Warburg effect, represents a hallmark of cancer cells. The spike protein causes this shift by impairing mitochondrial function and activating pathways including PI3K/Akt/mTOR, along with transcription factors HIF-1α, p53, and c-Myc. These changes result in increased hexokinase activity and glucose uptake, creating metabolic conditions that favor cancer cell proliferation.
Supporting this mechanism, von Ranke and colleagues identified significant mitochondrial electron transport dysfunction in their transcriptomic analysis of individuals with post-vaccination adverse events. Their data showed enrichment of gene sets related to mitochondrial complex dysfunction, particularly involving PINK1, ABETA, and SNCA variants, suggesting convergent disruption of cellular energy metabolism.
Disruption of Tumor Suppressor Pathways
Multiple studies have documented direct interactions between spike protein components and critical tumor suppressor proteins. Valdes Angues and Perea Bustos reported that the S2 subunit of the spike protein specifically interacts with p53, BRCA1, and BRCA2 proteins. These interactions potentially sequester these crucial tumor suppressors in the cytoplasm, preventing their nuclear function in DNA repair and cell cycle regulation.
Marik and Hope expand on this mechanism, noting that spike protein disrupts p53’s ability to activate apoptosis-related genes like p21 and TRAIL DR5, particularly after chemotherapy exposure. This interference with programmed cell death allows damaged cells to survive and potentially undergo malignant transformation.
Immune System Dysfunction
Both patient cohorts studied by von Ranke’s team showed widespread immune dysregulation. Their transcriptomic analysis revealed systemic inflammatory responses with significant enrichment of pathways involving naive CD4/CD8 T cells, polymorphonuclear leukocytes, and altered humoral immune responses. This immune perturbation creates conditions favorable to cancer development.
Valdes Angues and Perea Bustos documented post-vaccination lymphopenia, characterized by decreased T cell counts that persist for weeks. This lymphocyte depletion, particularly of CD8+ T cells, releases the immunological brakes that normally prevent dormant cancer cells from proliferating. The authors note that similar lymphopenia patterns in HIV patients and organ transplant recipients correlate with increased cancer risk.
Transcriptomic Instability and Cellular Stress
Von Ranke’s transcriptomic analysis revealed profound cellular stress responses in both patient groups studied. Individuals with new-onset adverse events showed significant upregulation of proteasome-mediated protein degradation pathways, suggesting accumulation of misfolded proteins requiring clearance. This proteostatic stress, combined with enrichment of nonsense-mediated decay pathways and ribosomal stress markers, indicates sustained cellular dysfunction.
The cancer cohort displayed even more concerning patterns, with additional signatures of genomic instability and epigenetic reprogramming. Gene sets related to DNA methylation, chromatin remodeling, and cell cycle checkpoint disruption were significantly enriched, suggesting fundamental alterations in genomic regulation.
Proliferative Signaling and Angiogenesis
Multiple pathways promoting cellular proliferation appear activated following vaccination. Von Ranke’s analysis identified MYC activation and suppression of p53 networks in both patient groups. Simultaneously, genes involved in angiogenesis showed dysregulation, with downregulation of pathways that normally limit blood vessel formation.
Marik and Hope describe how spike protein promotes angiogenesis through VEGF upregulation, linked to dysregulation of the renin-angiotensin system via ACE2 downregulation. The spike protein’s structural homology with human galectin-3 enables it to mimic this protein’s role in promoting cancer aggressiveness and metastasis.
Additional Contributing Mechanisms
Beyond the primary pathways, researchers have identified several additional mechanisms that may contribute to post-vaccination cancer development. These include reactivation of oncogenic viruses such as Epstein-Barr virus, which can modulate metabolic pathways and inhibit apoptosis. The detection of SV40 DNA sequences in vaccine vials raises concerns about exposure to known oncogenic elements. Additionally, the codon optimization used in vaccine design may dysregulate RNA G-quadruplex protein binding systems, altering translational regulation of cellular microRNAs critical for maintaining normal cellular function.
Clinical Implications and Risk Stratification
The convergence of biological mechanisms with clinical observations suggests certain populations may face elevated cancer risk following vaccination. These include individuals with strong family histories of cancer, patients in remission from prior malignancies, elderly individuals over 75 years, and those who have received multiple booster doses. The temporal association between booster administration and cancer recurrence appears particularly concerning.
The Path Forward
The dismissal of these observations as “biologically implausible” contradicts the substantial mechanistic evidence emerging from multiple independent research groups. The transcriptomic signatures identified by von Ranke and colleagues provide objective molecular evidence of cellular disruption that aligns with the theoretical mechanisms proposed by Valdes Angues and the clinical patterns documented by Marik.
What we need now is systematic investigation rather than reflexive dismissal. This includes long-term surveillance of cancer incidence in vaccinated populations, mechanistic studies examining spike protein interactions with tumor suppressor pathways, investigation of dose-response relationships between vaccination frequency and cancer outcomes, and development of biomarkers to identify individuals at elevated risk.
Conclusion
The accumulating evidence from transcriptomic analyses, mechanistic studies, and clinical observations presents a coherent picture of potential cancer risk following COVID-19 vaccination. The multi-hit hypothesis proposed by Valdes Angues and Perea Bustos provides a framework for understanding how multiple converging mechanisms—metabolic reprogramming, immune dysfunction, genomic instability, and tumor suppressor disruption—might collectively promote oncogenesis.
While these findings do not negate the role vaccines played during the acute pandemic, they fundamentally alter risk-benefit calculations for ongoing vaccination programs. The possibility that vaccines might accelerate cancer development through multiple biological pathways demands rigorous investigation. Science advances through careful examination of unexpected observations, not through adherence to predetermined conclusions. The health of millions depends on our willingness to follow the evidence wherever it leads.
References
Marik P, Hope J. COVID-19 mRNA-Induced “Turbo Cancers”. J Indep Med. 2025;1(3):185-194.
von Ranke N, Zhang W, Anokin P, Hulscher N, McKernan KJ, McCullough PA, Catanzaro JA. Synthetic mRNA Vaccines and Transcriptomic Dysregulation: Evidence from New-Onset Adverse Events and Cancers Post-Vaccination. Preprints.org [Preprint]. 2025 Jul 25. (Note: This article is currently a preprint and has not undergone peer review. The preprint status means it has not yet been published in a peer-reviewed journal, though it presents preliminary research findings that are part of the ongoing scientific discussion about vaccine safety monitoring.)
